IDENTIFICATION OF WILD-TYPE AND MUTANT P53 PEPTIDES BINDING TO HLA-A2ASSESSED BY A PEPTIDE LOADING-DEFICIENT CELL-LINE ASSAY AND A NOVEL MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I PEPTIDE BINDING ASSAY
G. Stuber et al., IDENTIFICATION OF WILD-TYPE AND MUTANT P53 PEPTIDES BINDING TO HLA-A2ASSESSED BY A PEPTIDE LOADING-DEFICIENT CELL-LINE ASSAY AND A NOVEL MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I PEPTIDE BINDING ASSAY, European Journal of Immunology, 24(3), 1994, pp. 765-768
Mutations of the p53 gene are the most frequently observed genetic cha
nges in human cancers; often leading to an overexpression of the wild-
type (wt) p53 protein. Demonstrable T cell reactivity against tumor ce
lls overexpressing wt or mutant p53-derived peptides could support the
application of such epitopes in cancer immunotherapies. As the bindin
g of peptide to MHC class I molecules is a prerequisite for antigen-sp
ecific T cell recognition, we evaluated the ability of wt and mutant p
53 peptides to bind to HLA-A2.1 using two independent flow cytometry-b
ased assay systems, the T2 major histocompatibility complex (MHC) clas
s I peptide stabilization assay (stabilization assay) and the peptide-
induced MHC class I reconstitution assay (reconstitution assay). The t
wenty selected wt sequences each conformed to the previously reported
HLA-A2.1 peptide binding motif. Seven of the wt p53 and 2/13 mutant p5
3 peptides derived from the previously chosen wt peptides bound to HLA
-A2.1 in both the stabilization and the reconstitution assays. An addi
tional six wt and six mutant p53 peptides, presumably exhibiting lower
affinity for HLA-A2.1, were identified only in the reconstitution ass
ay. Those p53 peptides binding HLA-A2.1 may provide useful immunogens
for the generation of HLA-A2.1-restricted cytolytic T lymphocytes in v
itro and in vivo.